Jazz Pharmaceuticals plc (JAZZ) Institutional Ownership

Ownership Summary

The institutional landscape for Jazz Pharmaceuticals plc (NASDAQ:JAZZ) includes 495 filers as of the latest reporting cycle ending September 2025.

• The percentage of Jazz Pharmaceuticals owned by institutions changed from 99.7% in June 2025 to 100.4% in September 2025, marking a slight up trend.
• The company experienced a -2.30% quarterly change in institutional shares held, alongside an increase of 5.10% in total owners annually.
• Of these 495 institutional investors, 196 increased their holdings in Jazz Pharmaceuticals, while 221 of them reduced positions, and 78 investors maintained their exposure.
• This class of investors decreased its holdings in Jazz Pharmaceuticals to 60.91Mn shares for the 13F-cycle ending September 2025, down by 1.44Mn shares quarter on quarter, and up 3.57Mn shares year over year.
• The top institutional stake in Jazz Pharmaceuticals as of September 30, 2025 belongs to VANGUARD GROUP INC, which owns 5.91Mn shares, or 9.74% of the company.
• Among the most significant buyers of Jazz Pharmaceuticals during September 2025 were GOLDENTREE ASSET MANAGEMENT LP (1.14Mn), Schonfeld Strategic Advisors LLC (373.38K), DIMENSIONAL FUND ADVISORS LP (298.81K), Woodline Partners LP (232.28K), JANE STREET GROUP, LLC (226.26K).
• Leading sellers of Jazz Pharmaceuticals stock in September 2025 included Vestal Point Capital, LP (700.00K), MILLENNIUM MANAGEMENT LLC (417.59K), Perpetual Ltd (284.94K), Logos Global Management LP (250.00K), MORGAN STANLEY (248.12K).
• The top 10 institutional holders of Jazz Pharmaceuticals for the quarter ending September 2025 included VANGUARD GROUP INC (5.91Mn), BlackRock, Inc. (5.56Mn), DIMENSIONAL FUND ADVISORS LP (2.84Mn), Capital World Investors (2.55Mn), LSV ASSET MANAGEMENT (2.51Mn), STATE STREET CORP (1.87Mn), JPMORGAN CHASE & CO (1.87Mn), AMERIPRISE FINANCIAL INC (1.85Mn), EcoR1 Capital, LLC (1.71Mn), FULLER & THALER ASSET MANAGEMENT, INC. (1.63Mn).